Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
OncoSec Medical Incorporated is a biotechnology business based in the US. OncoSec Medical Incorporated shares (ONCS) are listed on the NASDAQ and all prices are listed in US Dollars. OncoSec Medical Incorporated employs 42 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$1.72|
|52-week range||$1.75 - $8.16|
|50-day moving average||$2.09|
|200-day moving average||$3.11|
|Wall St. target price||$10.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.47|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-16.50%|
|1 month (2021-09-23)||-20.74%|
|3 months (2021-07-23)||-22.87%|
|6 months (2021-04-23)||-64.54%|
|1 year (2020-10-23)||-53.39%|
|2 years (2019-10-23)||-24.73%|
|3 years (2018-10-23)||1.78|
|5 years (2016-10-21)||1.78|
|Gross profit TTM||$0|
|Return on assets TTM||-55.59%|
|Return on equity TTM||-122.53%|
|Market capitalisation||$80.7 million|
TTM: trailing 12 months
There are currently 867,587 OncoSec Medical Incorporated shares held short by investors – that's known as OncoSec Medical Incorporated's "short interest". This figure is 2.3% down from 888,456 last month.
There are a few different ways that this level of interest in shorting OncoSec Medical Incorporated shares can be evaluated.
OncoSec Medical Incorporated's "short interest ratio" (SIR) is the quantity of OncoSec Medical Incorporated shares currently shorted divided by the average quantity of OncoSec Medical Incorporated shares traded daily (recently around 171459.88142292). OncoSec Medical Incorporated's SIR currently stands at 5.06. In other words for every 100,000 OncoSec Medical Incorporated shares traded daily on the market, roughly 5060 shares are currently held short.
However OncoSec Medical Incorporated's short interest can also be evaluated against the total number of OncoSec Medical Incorporated shares, or, against the total number of tradable OncoSec Medical Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case OncoSec Medical Incorporated's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 OncoSec Medical Incorporated shares in existence, roughly 20 shares are currently held short) or 0.0542% of the tradable shares (for every 100,000 tradable OncoSec Medical Incorporated shares, roughly 54 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against OncoSec Medical Incorporated.
Find out more about how you can short OncoSec Medical Incorporated stock.
We're not expecting OncoSec Medical Incorporated to pay a dividend over the next 12 months.
OncoSec Medical Incorporated's shares were split on a 1:10 basis on 20 May 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your OncoSec Medical Incorporated shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for OncoSec Medical Incorporated shares which in turn could have impacted OncoSec Medical Incorporated's share price.
Over the last 12 months, OncoSec Medical Incorporated's shares have ranged in value from as little as $1.75 up to $8.1598. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OncoSec Medical Incorporated's is 2.173. This would suggest that OncoSec Medical Incorporated's shares are significantly more volatile than the average for this exchange and represent a higher risk.
OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and new DNA-encoded therapeutic candidates and tumor indications to treat deep visceral lesions, such as liver, lung, bladder, pancreatic, and other visceral lesions. It has clinical trial collaborations with Merck & Co. , Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate enhanced IL-12 DNA-plasmid; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.